EpiCept to Report First Quarter 2009 Operating and Financial Results on May 7, 2009

EpiCept to Report First Quarter 2009 Operating and Financial Results on May 7,
2009

TARRYTOWN, N.Y.--(BUSINESS WIRE)--  

EpiCept Corporation (Nasdaq and OMX Nordic Exchange: EPCT) today announced that
it will host a conference call to discuss first quarter 2009 operating and
financial results on Thursday, May 7, 2009 at 9:00 a.m. Eastern time. The call
will follow the release of these financial results earlier in the day at 12:01
a.m. Eastern time. 

To participate in the live call, please dial from the U.S. or Canada (877)
809-8594 or from international locations (706) 758-9407 (please reference access
code 97888197). The conference call will also be broadcast live on the Internet
and may be accessed at www.epicept.com. The web cast will be archived for 90
days. 

A telephone replay of the call will be available for seven days by dialing from
the U.S. and Canada (800) 642-1687 or from international locations (706)
645-9291 (please reference reservation number 97888197). 

About EpiCept Corporation 

EpiCept is focused on unmet needs in the treatment of cancer and pain. The
Company's broad portfolio of pharmaceutical product candidates includes
Ceplene®, a cytokine immunomodulator that recently received marketing
authorization in Europe for the remission maintenance of AML patients, and pain
therapies that are in clinical development. Two oncology drug candidates
currently in clinical development that were discovered using in-house technology
have also been shown to act as vascular disruption agents in a variety of solid
tumors. 

Forward-Looking Statements 

This news release and any oral statements made with respect to the information
contained in this news release, contains forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995. Such
forward-looking statements include statements which express plans, anticipation,
intent, contingency, goals, targets, future development and are otherwise not
statements of historical fact. These statements are based on our current
expectations and are subject to risks and uncertainties that could cause actual
results or developments to be materially different from historical results or
from any future results expressed or implied by such forward-looking statements.
Factors that may cause actual results or developments to differ materially
include: the risk that the stockholders will not approve the aforementioned
items or that we will not have sufficient authorized shares of stock to raise
equity capital, the risks associated with the adequacy of our existing cash
resources and our ability to continue as a going concern, the risks associated
with our ability to continue to meet our obligations under our existing debt
agreements, the risk that our securities may be delisted by The Nasdaq Capital
Market or the OMX Nordic Exchange and that any appeal of the delisting
determination may not be successful, the risk that Ceplene® will not receive
regulatory approval or marketing authorization in the United States or Canada,
the risk that Ceplene® will not be launched in Europe in the second half of 2009
or achieve significant commercial success, the risk that we are unable to find a
suitable marketing partner for Ceplene® on attractive terms, a timely basis or
at all, the risk that any required post-approval clinical study for Ceplene®
will not be successful, the risk that we will not be able to maintain our final
regulatory approval or marketing authorization for Ceplene®, the risk that
Myriad's development of Azixa™ will not be successful, the risk that Azixa™ will
not receive regulatory approval or achieve significant commercial success, the
risk that we will not receive any significant payments under our agreement with
Myriad, the risk that the development of our other apoptosis product candidates
will not be successful, the risk that we will not be able to find a buyer for
our ASAP technology, the risk that clinical trials for EpiCeptTM NP-1 or
crinobulin will not be successful, the risk that EpiCeptTM NP-1 or crinobulin
will not receive regulatory approval or achieve significant commercial success,
the risk that we will not be able to find a partner to help conduct the Phase
III trials for EpiCeptTM NP-1 on attractive terms, a timely basis or at all, the
risk that our other product candidates that appeared promising in early research
and clinical trials do not demonstrate safety and/or efficacy in larger-scale or
later stage clinical trials, the risk that we will not obtain approval to market
any of our product candidates, the risks associated with dependence upon key
personnel, the risks associated with reliance on collaborative partners and
others for further clinical trials, development, manufacturing and
commercialization of our product candidates; the cost, delays and uncertainties
associated with our scientific research, product development, clinical trials
and regulatory approval process; our history of operating losses since our
inception; the highly competitive nature of our business; risks associated with
litigation; and risks associated with our ability to protect our intellectual
property. These factors and other material risks are more fully discussed in our
periodic reports, including our reports on Forms 8-K, 10-Q and 10-K and other
filings with the U.S. Securities and Exchange Commission. You are urged to
carefully review and consider the disclosures found in our filings which are
available at www.sec.gov or at www.epicept.com. You are cautioned not to place
undue reliance on any forward-looking statements, any of which could turn out to
be wrong due to inaccurate assumptions, unknown risks or uncertainties or other
risk factors. 

EPCT-GEN 

*Azixa is a registered trademark of Myriad Genetics, Inc. 


EpiCept Corporation:
Robert W. Cook, 914-606-3500
rcook@epicept.com
or
Media:
Feinstein Kean Healthcare
Greg Kelley, 617-577-8110
gregory.kelley@fkhealth.com
or
Investors:
Lippert/Heilshorn & Associates
Kim Sutton Golodetz, 212-838-3777
kgolodetz@lhai.com
or
Bruce Voss, 310-691-7100
bvoss@lhai.com